Company intelligence / Profile preview

NitricGen

USA

Ownership: Private
Development stage: Other

Overview

NitricGen developed the eNOGenerator, a novel device for gaseous nitric oxide delivery, tested for wound healing and pulmonary applications. The technology was licensed to AIT Therapeutics, with 91 safe treatments completed in early studies for lung infections and development targeting FDA submission and commercial use in pulmonary hypertension, bronchiolitis, and NTM.

Therapeutic areas: Infectious DiseasesDermatologyCardiovascularPulmonology
Modalities: DeviceSmall molecule
Industry: Therapeutic Medical Devices

Partnerships

AIT Therapeutics

Beyond the preview

Go deeper on NitricGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NitricGen.

Explore the full profile